[New developments in hypericum extracts: data on efficacy and interactions].
The recent clinical studies on hypericum extract support the present indications for its use in mild to moderate depression and depressive episodes. The effectiveness is superior to placebo and comparable with synthetic antidepressive drugs. The rate of unwanted events is explicitly lower and their severity in general only mild. A further indication for hypericum could be somatoform disorders, but further clinical studies are recommended. The main compound responsible for interactions is presumably hyperforin, but further ingredients could contribute according to the specific composition of the particular extract.
Kraft
Karin
K
Klinik und Poliklinik für Innere Medizin, Lehrstuhl für Naturheilkunde, Rostock, Germany. karin.kraft@med.uni-rostock.de
D000293:Adolescent; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use; D001643:Bridged Bicyclo Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D015283:Citalopram / Q000008:administration & dosage / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy*; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D020902:Hypericum; D008297:Male; D010696:Phloroglucinol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D008517:Phytotherapy / Q000009:adverse effects; D010919:Placebos; D010936:Plant Extracts / Q000627:therapeutic use; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013001:Somatoform Disorders / Q000188:drug therapy; D013729:Terpenes / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D001643:Bridged Bicyclo Compounds; D015283:Citalopram; D005473:Fluoxetine; D010696:Phloroglucinol; D010919:Placebos; D010936:Plant Extracts; D017367:Selective Serotonin Reuptake Inhibitors; D013729:Terpenes; C001654:hyperforin
Pharmacopsychiatry. 2006 Mar;39(2):66-75
16555167
Psychosom Med. 2004 Jul-Aug;66(4):538-47
15272100
Br J Dermatol. 2005 Dec;153(6):1187-91
16307656
Clin Pharmacokinet. 2006;45(5):449-68
16640452
BMC Med. 2006 Jun 23;4:14
16796730
Phytomedicine. 2006 Feb;13(3):199-204
16428030
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000448
15846605
Eur J Clin Pharmacol. 2006 Mar;62(3):225-33
16477470
J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):197-206
16553540
Oncologist. 2006 Jul-Aug;11(7):742-52
16880233
BMJ. 2004 Jul 3;329(7456):27-30
15231618
Arzneimittelforschung. 2006;56(3):212-21
16618014
Altern Med Rev. 2005 Mar;10(1):5-13
15771558
Eur Arch Psychiatry Clin Neurosci. 2005 Feb;255(1):40-7
15538592
J Clin Psychopharmacol. 2005 Feb;25(1):51-8
15643100
Int Clin Psychopharmacol. 2005 Nov;20(6):299-304
16192837
Pharmacopsychiatry. 2005 Mar;38(2):78-86
15744631
Contraception. 2005 Jun;71(6):402-8
15914127
J Clin Psychopharmacol. 2005 Oct;25(5):441-7
16160619
J Child Adolesc Psychopharmacol. 2005 Apr;15(2):293-301
15910213
BMJ. 2005 Mar 5;330(7490):503
15708844
Phytomedicine. 2006 Mar;13(4):215-21
16423519
Pharmacopsychiatry. 2005 Sep;38(5):194-200
16189745
J Clin Psychiatry. 2006 Feb;67(2):305-9
16566628
Can J Clin Pharmacol. 2006 Fall;13(3):e268-76
17085775
Br J Clin Pharmacol. 2006 Nov;62(5):512-26
17010103
J Pharmacol Sci. 2006 Sep;102(1):47-54
16936454